• Kyle Gregory Halvorson, Kelly L Barton, Kristin Schroeder, Katherine Misuraca, Christine Hoeman, Alex Chung, Donna Crabtree, Francisco Cordero, Raj Singh, Ivan Spasojevic, Noah Berlow, Ranadip Pal, and Oren Becher.
• Neurosurgery. 2015 Aug 1;62 Suppl 1:211.

IntroductionDiffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type of pediatric brain cancer with no effective therapeutic options. Our laboratory has previously reported the development of genetically engineered DIPG mouse models by using the RCAS/tv-a system, including a model driven by PDGF-B, H3.3K27M, and p53 loss. These models can serve as a platform in which to test novel therapeutics before the initiation of human clinical trials.MethodsIn this study, an in vitro high-throughput drug screen as part of the DIPG preclinical consortium using cell lines derived from our DIPG models identified BMS-754807 as a drug of interest in DIPG. BMS-754807 is a potent and reversible small-molecule multikinase inhibitor with many targets, including IGF-1R, IR, MET, TRKA, TRKB, AURKA, and AURKB.ResultsIn vitro evaluation showed significant cytotoxic effects with an IC50 of 0.13 μM, significant inhibition of proliferation at a concentration of 1.5 μM, as well as inhibition of AKT activation. Interestingly, IGF-1R signaling was absent in serum-free cultures from the PDGF-B, H3.3K27M, p53 deficient model suggesting that the antitumor activity of BMS-754807 in this model is independent of IGF-1R. In vivo, systemic administration of BMS-754807 to DIPG-bearing mice did not prolong survival. Pharmacokinetic analysis demonstrated that tumor tissue drug concentrations of BMS-754807 were well below the identified IC50, suggesting that inadequate drug delivery may limit in vivo efficacy.ConclusionIn summary, an unbiased in vitro drug screen identified BMS-754807 as a potential therapeutic agent in DIPG, but BMS-754807 treatment in vivo by systemic delivery did not significantly prolong survival of DIPG-bearing mice.

17 keywords...

hide…